Franklin Resources Inc. Acquires New Stake in Artiva Biotherapeutics, Inc. (NASDAQ:ARTV)

Franklin Resources Inc. acquired a new position in shares of Artiva Biotherapeutics, Inc. (NASDAQ:ARTV - Free Report) in the third quarter, according to its most recent 13F filing with the Securities & Exchange Commission. The institutional investor acquired 520,301 shares of the company's stock, valued at approximately $7,435,000. Franklin Resources Inc. owned 2.14% of Artiva Biotherapeutics as of its most recent filing with the Securities & Exchange Commission.

Several other hedge funds and other institutional investors have also added to or reduced their stakes in ARTV. Charles Schwab Investment Management Inc. acquired a new position in shares of Artiva Biotherapeutics during the third quarter valued at approximately $623,000. BNP Paribas Financial Markets purchased a new stake in shares of Artiva Biotherapeutics during the third quarter worth approximately $42,000. MetLife Investment Management LLC acquired a new position in Artiva Biotherapeutics in the 3rd quarter valued at $135,000. Acuta Capital Partners LLC purchased a new position in Artiva Biotherapeutics in the 3rd quarter valued at $680,000. Finally, RTW Investments LP acquired a new stake in Artiva Biotherapeutics during the 3rd quarter worth $2,300,000.

Artiva Biotherapeutics Trading Down 5.7 %

Shares of ARTV stock traded down $0.63 on Monday, hitting $10.48. 58,521 shares of the stock traded hands, compared to its average volume of 120,553. Artiva Biotherapeutics, Inc. has a twelve month low of $9.68 and a twelve month high of $17.31. The company's 50-day moving average price is $11.57.

Artiva Biotherapeutics (NASDAQ:ARTV - Get Free Report) last posted its earnings results on Tuesday, November 12th. The company reported ($0.92) earnings per share for the quarter, missing the consensus estimate of ($0.68) by ($0.24). As a group, equities research analysts predict that Artiva Biotherapeutics, Inc. will post -4.68 EPS for the current year.

Wall Street Analysts Forecast Growth

ARTV has been the topic of several research reports. Wedbush reissued an "outperform" rating and issued a $18.00 price target on shares of Artiva Biotherapeutics in a research note on Friday, August 30th. Needham & Company LLC reissued a "buy" rating and issued a $23.00 target price on shares of Artiva Biotherapeutics in a research note on Wednesday, November 13th. Five analysts have rated the stock with a buy rating, According to data from MarketBeat, Artiva Biotherapeutics currently has a consensus rating of "Buy" and a consensus price target of $21.25.

Artiva Biotherapeutics Profile

Artiva Biotherapeutics, Inc, a clinical-stage biotechnology company, focuses on developing natural killer (NK) cell-based therapies for patients suffering from autoimmune diseases and cancers. The company's lead product candidate is AB-101, an off-the-shelf NK cell therapy for patients with autoimmune diseases and cancers, such as lupus nephritis, rheumatoid arthritis, pemphigus vulgaris, the anti-neutrophil cytoplasmic antibody-associated vasculitis subtypes granulomatosis with polyangiitis/microscopic polyangiitis, systemic lupus erythematosus, and B-cell-non-Hodgkin lymphoma.